Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...
Abbott has been given U.S. clearance for new updates to its CardioMEMS HF System that allow for patient-facing capabilities ...
Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European ...
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.
Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...
The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. | The FDA has approved a surgically implanted pulmonary heart valve ...
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...
As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results